Table 1 Demographics and clinical characteristics of the patients

Male/Female

62/63

Age (mean ± SD, years)

62.37 ± 14.11

BMI (mean ± SD, kg/m2)

22.80 ± 3.136

Ever-smoker (n, %)

36/124, 25.44%

 Smoking Index (median, IQR)

560 (270, 800)

Respiratory symptoms (n, %)

 Cough

120/125, 96.0%

 Sputum

118/125, 94.4%

 Hemoptysis

42/125, 33.6%

 Dyspnea

55/125, 44.0%

Annual exacerbations (median, IQR)

1.0 (1.0, 2.0)

Blood test

 WBC (10⁹/l, median, IQR)

6.40 (5.13, 7.84)

 HB (g/l, median, IQR)

132.3 ± 18.07

 Neutrophil (10⁹/l, median, IQR)

4.01 (3.00, 5.02)

 Eosinophil (%, median, IQR)

2.20 (1.40, 3.60)

 Eosinophil (cell/ul, median, IQR)

140 (90, 230)

 Total IgE (KU/L, median, IQR)

47.7 (19.8, 123.0)

 Specific IgE to Aspergillus fumigatus (n, %)

3/125, 2.4%

Sputum culture

89/125, 72.2%

 Isolation of any pathogenic bacteria

22/89, 24.7%

 Isolation of Pseudomonas aeruginosa

15/22, 68.2%

Chest HRCT

 Number of lobes involved (median, IQR)

4 (2, 5)

 ≥ 3 lobes involved (n, %)

87/125, 69.6%

 Bilateral involvement(n, %)

86/125, 68.8%

 Lobes involved (n, %)

  Upper lobes

76/125, 60.8%

  Middle/ lingula lobe

103/125, 82.4%

  Lower lobes

117/125, 93.6%

 Smith score(median, IQR)

7 (4, 11)

 Bhalla score(median, IQR)

6 (3, 10)

 Bronchiectasis type (n, %)

  Cylindrical

38/125, 30.4%

  Cystic and/or mixed

87/125, 69.6%

  Mucus plugs

21/125, 16.8%

Lung function (n = 125)

 FEV₁% predicted (%, median, IQR)

73.0 (49.4, 86.7)

 FEV₁/FVC (%, median, IQR)

71.0 (56.7, 77.3)

 RV/TLC (mean ± SD, years)

50.3 ± 12.92

Treatment

 ICS + LABA

10/125, 8%

 LABA + LAMA

2/125, 1.6%

 Long-term(> 2 wk)macrolides*

3/125, 2.4%

BSI score (median, IQR)

9.0 (7.0, 13.0)

 0–4

16/89, 18.0%

 5–8

25/89, 28.1%

 ≥9

48/89, 53.9%

E-FACED score (median, IQR)

2.0 (1.0, 4.0)

 0–3

53/89, 59.6%

 4–6

31/89, 34.8%

 7–9

5/89, 5.6%